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ABSTRACT
The Association of Urinary Polycyclic Aromatic Hydrocarbons and Markers of
Inflammation, Diabetes Mellitus and Cardiovascular Disease
Omayma Alshaarawy

Polycyclic aromatic hydrocarbons are potent atmospheric pollutants, released into air
during incomplete combustion of fuel, industrial or domestic coal, wood, cigarette smoke and
other organic materials. In addition to being carcinogenic, several animal studies have reported
positive associations between polycyclic aromatic hydrocarbons and inflammation, oxidative
stress and the development and progression of atherosclerosis. Occupational studies have
reported positive associations between polycyclic aromatic hydrocarbons and cardiovascular
morbidity and mortality. Moreover, there is evidence that polycyclic aromatic hydrocarbons may
cause disruption of the endocrine system. It is still not clear if lower background exposure to
polycyclic aromatic hydrocarbons, independent of the adverse health effects of smoking, is
associated with increased risk of inflammation, diabetes mellitus and cardiovascular disease in
the general population. We examined participants from the merged National Health and
Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our exposures of interest
were eight urinary monohydroxy polycyclic aromatic hydrocarbons and our outcomes were
serum markers of systemic inflammation, including: serum C-reactive protein and total white
blood cell count, diabetes mellitus and self-reported cardiovascular disease. Urinary biomarkers
of the low molecular weight polycyclic aromatic hydrocarbons were found to be positively
associated with serum C-reactive protein, total white blood cell count and diabetes mellitus
independent of potential confounders. Levels of 1-hydroxypyrene, the urinary metabolite of the
higher molecular weight PAH, pyrene, showed a less strong association with serum C-reactive
protein and diabetes mellitus. The evidence on the association between polycyclic aromatic
hydrocarbons and self-reported cardiovascular disease was limited, only 1-hydroxynapthalene,
summed biomarkers of low molecular weight polycyclic aromatic hydrocarbons, and 1hydroxypyrene showed statistically significant positive associations with cardiovascular disease
independent of potential confounders. In conclusion, this study provides evidence on the positive
association of background exposure to polycyclic aromatic hydrocarbons and serum C-reactive
protein, total white blood cell count, diabetes mellitus and cardiovascular disease. Further
prospective studies are needed to replicate or refute our findings.
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INTRODUCTION

Rationale for studying systemic inflammation, diabetes mellitus and CVD
Despite advances in prevention, diagnosis and treatment, cardiovascular disease (CVD)
remains the number one cause of mortality in United States (US) adults.[1] Diabetes mellitus is a
major risk factor for CVD [2, 3] and the seventh leading cause of death in the US.[4] Systemic
inflammation is considered a key risk factor for atherosclerosis and subsequent development of
CVD.[5] Inflammation has been also known to associate with insulin resistance and diabetes
mellitus.[6] Several studies have reported positive association between baseline elevations of the
serum inflammatory marker C-reactive protein (CRP) and risk of CVD and diabetes mellitus.[7,
8] Moreover, elevation in total white blood cells (WBC) count within the normal range was
found to be independently associated with CVD and diabetes mellitus.[9, 10]

Environmental pollutants and systemic inflammation, diabetes mellitus and CVD
Several studies have suggested that exposure to particulate matter present in ambient air
is associated with increased CVD. Recent evidence has suggested that smaller particles and gases
may pose a greater CVD risk, possibly through development of atherosclerosis.[11] In addition,
studies have suggested that common environmental exposures , such as Dioxins [12] (group of
halogenated aromatic hydrocarbons), affecting large sections of the population may be a
determinant of diabetes risk [13, 14] as well as CVD risk.[15]

Polycyclic aromatic hydrocarbons
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Polycyclic aromatic hydrocarbons (PAHs) are environmental and occupational
carcinogens released into air during incomplete combustion of fuel, industrial or domestic coal,
wood, and grilled or smoked food.[16, 17] Active smoking and second-hand smoke (SHS)
exposure are major sources of PAHs.[18] Individuals without occupational or tobacco smoke
exposure are believed to be exposed primarily to PAHs through food contaminated with
PAHs.[19] The total intake of PAHs in the general population has been estimated to be 3
μg/day.[20]
Polycyclic aromatic hydrocarbons are found within the environment in either a gaseous
or particulate form.[21] PAHs with the lowest molecular weight (naphthalene, fluorene, and
phenanthrene) have low vapor pressures, and are found mainly in a gaseous form. Polycyclic
aromatic hydrocarbons with higher molecular weights (pyrene) have higher vapor pressures and
are found in a particulate form. Individuals exposed to PAHs via inhalation of the ambient air are
exposed to both low molecular weight (LMW) PAHs and higher molecular weight PAHs.
Humans are also exposed to the higher molecular weight PAHs through gastrointestinal
absorption of contaminated food or water and/or skin absorption of PAH particles.[22]
Polycyclic aromatic hydrocarbons were found to have high affinity for lipid-rich tissues
such as mammary and adipose tissues.[23] Irrespective of the route of administration, PAHs are
rapidly and widely distributed in the body. Detectable levels of PAHs can be observed in most
internal organs following exposure.[4] Researchers have examined PAHs directly in the blood
and tissues of experimental animals. However, these methods have not been widely used for
humans due to the high costs and the limited clinical significance of testing. The most commonly
used biomarkers of PAH exposure are urinary monohydroxy-PAH (OH-PAH). Urinary OH-PAH
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has been found to correlate well with levels of exposure to PAHs in the general populations.[24]
Additional effects of human occupational exposures can be detected using urinary PAH
biomarkers, independent of smoking.[25]

PAHs and systemic inflammation, diabetes mellitus and CVD
Considering the large number of deaths attributable to ambient air pollution, PAHs may
be a significant contributor to the high prevalence and mortality rate of diabetes mellitus and
cardiovascular disease. Several animal studies have reported positive associations between PAHs
and inflammation [26, 27], oxidative stress [28, 29] and the development and progression of
atherosclerosis.[30, 31] Exposure to PAHs triggers the Aryl hydrocarbon (AhR) –Xenobiotic
response element (XRE) signaling pathway and causes expression of proinflammatory genes. It
leads to inflammation that underlies development
of atherosclerosis. Activation of the AhR–XRE
pathway also induces expression of cytochrome
P450 (CYP) and subsequently generates reactive
oxygen species (ROS) and DNA adducts which
contributes to endothelial injury and consequent
atherosclerosis. Several studies have also
suggested that PAHs may cause disruption of the
endocrine system.[32]

Figure 1: Masanori Kitamura and Ayumi
Kasai, 2007
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In addition, several occupational studies have reported positive associations between
PAHs and cardiovascular morbidity [33, 34] and mortality.[35, 36] Two general populationbased studies have investigated the association between PAHs exposure and serum markers of
CVD using the National Health and Nutrition Examination Survey (NHANES), and the results
were inconsistent.[37, 38] Data on PAHs were withdrawn (and re-released) due to
inconsistencies in the laboratory methods used on NHANES 2001-2002 and 2003-2004 data
cycles. In addition, neither adjustment for active smoking and SHS exposure in addition to
confounders known to interact with the outcomes nor stratifying by major characteristics of the
study population was performed in those studies. The re-release of the data provides an
important opportunity for updated analysis.
The overall aim of this study was to investigate the independent association between
urinary levels of PAH biomarkers, including 1-hydroxynapthol, 2- hydroxynapthol, 2hydroxyfluorene, 3-hrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3hydroxyphenanthrene and 1-hydroxypyrene, and markers of systemic inflammation, diabetes
mellitus and CVD, among adult participants of NHANES, a large, multiethnic, population-based,
study representative of the general population of the United States adults (US). Since exposure to
active smoking and SHS are major sources of PAHs, we sought to determine if this relationship
was independent of serum cotinine, self-reported smoking status, in addition to the other
potential confounders.
Due to the multiple sources of PAHs in the environment, exposure to a single PAH
compound is implausible. Metabolism, and consequently health effects of exposure to multiple
PAHs were found to be different from that of exposure to an individual PAH compound.[39]
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Enzyme competition was evident in the metabolism of PAH mixtures, changing significantly the
metabolism patterns from that of individual PAHs.[39] Therefore in the current study, and
similar to analytical strategies employed by previous authors [40], we created a summed variable
as a measure of cumulative exposure to multiple low molecular weight PAHs simultaneously.

The specific aims of the current study were as follows:

1. To examine the independent association of urinary PAH biomarkers and serum markers
of systematic inflammation such as high sensitivity C-reactive protein and white blood
cell count.
2. To examine the independent association of urinary PAH biomarkers and diabetes
mellitus.
3. To examine the independent association of urinary PAH biomarkers and self-reported
cardiovascular disease.
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CHAPTER 1
The Association of Urinary Levels of Polycyclic Aromatic Hydrocarbon Biomarkers and
Serum Inflammatory Makers.

Abstract
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants, occurring
from both anthropogenic and natural sources. Several animal studies have reported a positive
association of PAHs with inflammation. However, it is not clear if lower background exposure to
PAHs in the general population is associated with systemic inflammation in humans. We
examined participants from the National Health and Nutrition Examination Survey 2001-2002,
2003-2004, and 2005-2006. Our exposures were eight urinary monohydroxy polycyclic aromatic
hydrocarbons (OH-PAH) and our outcomes were serum C-reactive protein (CRP) (<10 mg/L)
and total white blood cell (WBC) count (4000-12,000 cells/µL). Compared to those with
summed biomarkers of low-molecular weight (LMW) PAHs in the lowest quartile, the
multivariable odds ratios (95% confidence interval) of serum CRP ≥ 3 mg/L and high total WBC
count (defined as at or above the 95 percentile of total WBC count distribution) among those in
the highest quartile were 1.77 (1.13, 2.76) and 1.34 (1.12, 1.60) respectively. Levels of 1hydroxypyrene, the biomarker of the higher molecular weight PAH pyrene, was positively
associated with total WBC count, and to lesser extent with serum CRP. In subsequent analyses,
the positive association between LMW PAHs and serum CRP and total WBC count was found to
be present within the stratified subgroups. In conclusion, urinary levels of PAH biomarkers were
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found to be positively associated with serum CRP and total WBC count independent of smoking
and other potential confounders.
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Systemic inflammation is considered a key risk factor for atherosclerosis and subsequent
development of cardiovascular disease (CVD).[5] Several studies have reported a positive
association between baseline elevations of C-reactive protein (CRP), a serum inflammatory
maker, and future risk of CVD.[41, 42] Clinical and public health groups have recommended
serum CRP levels to be used as a CVD risk stratifying tool.[43] In addition, elevations in total
white blood cells (WBC) count within the normal range (4000-12,000 cells/uL) were found to be
independently associated with increased risk of CVD and have been proposed as an alternate
serum inflammatory marker.[44]
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants composed of
fused aromatic rings.[16, 21, 45] PAHs may occur in oil, coal, and tar deposits, and are produced
as byproducts of smoking, and indoor and outdoor fuel burning.[18, 46] PAHs can be also found
in contaminated water, and in food as a result of food processing, preparation, and cooking. [47,
48] Further, exposure to PAHs is markedly increased by cigarette smoking. Several in-vitro and
animal studies have reported a positive association between exposure to PAHs and systemic
inflammation. [28, 49-51] However, it is not clear if the lower background exposure to PAHs is
associated with inflammatory effects in humans in the general population.
In this context, we examined the association of eight urinary biomarkers of PAHs, the
monohydroxy-PAHs (OH-PAH), with serum CRP and total WBC count in a nationally
representative sample of United States (US) adults. Since exposure to active smoking and second
hand smoke are major sources of PAHs, we sought to determine if this relationship was
independent of serum cotinine, self-reported smoking status, and other potential confounders.
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Due to the multiple sources of PAHs in the environment, exposure to a single PAH
compound is implausible. Metabolism, and consequently health effects of exposure to multiple
PAHs were found to be different from that of exposure to an individual PAH compound.[39]
Enzyme competition was evident in the metabolism of PAH mixtures, changing significantly the
metabolism patterns from that of individual PAHs.[39] Therefore in the current study, and
similar to analytical strategies employed by previous authors [40], we created a summed variable
as a measure of cumulative exposure to multiple low molecular weight PAHs simultaneously.

METHODS
Study population

The present study is based on merged data from the 2001-2002, 2003-2004 and 20052006 National Health and Nutrition Examination Survey (NHANES). Detailed description of
NHANES study design and methods are available elsewhere.[52] NHANES included a stratified
multistage probability sample representative of the civilian non-institutionalized US population.
Selection was based on counties, blocks, households and individuals within households, and
included oversampling of non-Hispanic Blacks and Mexican Americans in order to provide
stable estimates of these groups. Out of 31,509 participants in NHANES 2001-2006, there were
11, 512 who were 20-65 years of age. Urinary PAH biomarkers were only measured in a
subsample of individuals. The subsample is nationally representative, but with a smaller analytic
sample size.
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We excluded participants with missing information on serum CRP or with CRP levels
>10 mg/L, indicating potential underlying non-cardiovascular causes of inflammation.[53] We
further excluded participants with missing information on serum cotinine level, or other
covariates included in the final CRP model. Similarly, to minimize the confounding effect of
infection, only subjects with a WBC count within the normal range (4000-12,000 cells/uL) were
included in the final WBC analysis. We also excluded participants with missing information on
total WBC count, or other covariates included in the final model.

Main outcome of interest: Serum inflammatory markers

High sensitivity serum C - reactive protein.
Serum CRP was measured using latex-enhanced nephelometry. Details of the laboratory
collection, processing, and analysis are available in the laboratory procedures manual.[54] High
CRP level was defined as ≥3 mg/dL, consistent with American Heart Association/Centers for
Disease Control & Prevention (AHA/CDC) guidelines for identifying subjects with high risk of
CVD.[7]
Total white blood cell count within normal values.
The methods used to derive WBC count are based on the Beckman Coulter method of
counting. High WBC count was defined as values at or above the 95th percentile of the study
population distribution, consistent with previous studies examining the association between total
WBC count within normal ranges and CVD risk.[10, 55]

Main exposure: Urinary levels of monohydroxy-PAH
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Urine specimens collected during the clinical exam portion of the survey were processed,
stored, and shipped to the Division of Environmental Health Laboratory Sciences, National
Center for Environmental Health, Centers for Disease Control and Prevention for analysis. The
specific analytes measured in this study were monohydroxy-PAH (OH-PAH). By evaluating
these analytes in urine, a measurement of the body burden from PAH exposure is obtained.[24]
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and analysis
using capillary gas chromatography combined with high resolution mass spectrometry (GCHRMS). Detailed specimen collection and processing instructions are discussed in the
NHANES Laboratory/Medical Technologists Procedures Manual (LPM).
Seven LMW PAH urinary biomarkers, Naphthalene biomarkers; 1- hydroxynaphthalene,
2- hydroxynaphthalene, Fluorene biomarkers; 2-hydroxyfluorene, 3-hydroxyfluorene,
Phenanthrene biomarkers; 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3hydroxyphenanthrene and 1-hydroxypyrene, the biomarker of the higher molecular weight PAH
pyrene, were consistently available in NHANES 2001-2006. All analytes were measured in the
same unit; ng/L. Urinary OH-PAH were corrected for urinary creatinine concentration, a urinary
marker of kidney function to adjust for urinary dilution.[56] Urinary levels of OH-PAH (ng/L)
were divided by urinary creatinine level (mg/dL) multiplied by 0.01; [(ng/L) ÷ (mg/dL*0.01)]
and expressed as nanogram per gram of creatinine (ng/g creatinine).

Exposure measurements
Information on age, gender, race/ethnicity, alcohol intake, income, diabetes and cigarette
smoking were obtained from a standardized questionnaire during a home interview. Alcohol
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consumption was categorized into none and alcohol drinker. Income-poverty ratio
(Income/poverty guideline) was used as a measure of the socioeconomic status. The Department
of Health and Human Services’ poverty guidelines were used as the poverty measure to calculate
this ratio. Smoking status was categorized into never smokers (smoked <100 cigarettes during
their lifetime), former smokers (smoked ⩾100 cigarettes during their lifetime and currently not
smoking), current smokers (smoked ⩾100 cigarettes during their lifetime and currently
smoking). Information on anthropometric, physical and laboratory components were obtained
during the medical examination center examination. Body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared. Seated blood pressure was measured
using a mercury sphygmomanometer according to the American Heart Association and
recommendations.[57] Up to 3 measurements were averaged for blood pressure.
Statistical analysis
Urinary levels of OH-PAH were analyzed both as continuous as well as categorical
variables. For analysis as continuous variables, urinary OH-PAH levels were log-transformed as
a result of their skewed distribution. Weighted Pearson correlation coefficients between
individual OH-PAH were calculated to evaluate the correlations between pairwise combinations
of all eight urinary metabolites. We created an additive LMW PAH biomarkers variable by
summing urinary levels of metabolites of the low molecular weight PAHs (naphthalene, fluorene
and phenanthrene).
We ran linear regression models to calculate the multivariable change and 95%
confidence interval (CI) in serum CRP and total WBC count with increasing individual and
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additive urinary OH-PAH levels. In addition, we ran logistic regression models to calculate the
multivariable odds ratio (OR) and 95% CI of high serum CRP (≥ 3 mg/L) and total WBC count
at or above the 95th percentile of the total WBC count distribution, for each higher urinary OHPAH quartile by using the lowest quartile as the referent. Variables were included in the model if
they satisfied two conditions; first, a plausible association with the main exposure/outcome, and
second, a > 10 percent change of odds ratio after adjusting for the potential. Accordingly, final
models were adjusted for age (years), sex (men, women), ethnicity (non-Hispanic White, nonHispanic Black, all others), poverty-income ratio (%), alcohol drinking (yes/no), diabetes
(absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine
(ng/mL) and systolic blood pressure (mm Hg).
To further ensure that the association is homogenous for subgroups, we performed
subgroup analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that
account for the unequal probabilities of selection, oversampling, and nonresponse in the
NHANES survey were applied for all analyses. Analyses were conducted using SAS (version
9.3, SAS Institute, Cary, NC) software. Standard errors were estimated using the Taylor series
linearization method.

RESULTS
Table 1 presents the baseline characteristics of the study population with CRP levels<10
mg/L. The study population was primarily non-Hispanic White (72.9%). Approximately one-half
(50.5%) were never smokers, and the remainder were former smokers (21.7%) and current
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smokers (27.8%). The arithmetic mean of serum cotinine level was 74.2 ng/mL. Tables 2 and 3
present the weighted percentiles and means of individual and additive LMW urinary OH-PAH
metabolites used in the final CRP and total WBC count analyses, respectively.
Table 4 present the results of the analyses examining the correlations between pairwise
combinations of all eight urinary metabolites in addition to serum cotinine. The results indicate
that significant correlations exist between all OH-PAH pairwise combinations, with Pearson
correlation coefficients that ranged from 0.41 to 0.93.
Tables 5 and 6 present the results of the linear regression analyses measuring the
association between urinary OH-PAH levels, serum CRP and total WBC count respectively.
Urinary levels of OH-PAH were positively associated with serum CRP levels independent of
potential confounders. All the associations were statistically significant except for 1hydroxynaphthalene, 3-hydroxyphenanthrene and 1-hydroxypyrene. Similarly urinary levels of
OH-PAH were positively associated with total WBC count independent of potential confounders.
Table 7 presents the odds ratio of the association between urinary levels of OH- PAH and
high CRP, defined as CRP levels ≥ 3 mg/L. Overall, urinary levels of OH-PAH were positively
associated with high CRP in the multivariable adjusted models. Using urinary OH-PAH levels as
continuous variables, the observed associations were still positive. Although positive, the
associations between urinary 3-hydroxyphenanthrene and serum CRP were not statistically
significant.
Table 8 presents the odds ratios of the association between urinary levels of OH-PAH and
high WBC count (defined as at or above the 95th percentile of the total WBC count distribution).
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Similar to the results for CRP, urinary levels of OH-PAH were positively associated with high
total WBC count in the multivariable adjusted models. Using urinary OH-PAH levels as
continuous variables, the observed associations were still positive. Although positive, the
associations between urinary 1-hydroxyphenanthrene and 3-hydroxyphenanthrene and total
WBC were not statistically significant.
Table 9 investigates several types of potential confounding. We performed subgroup
analyses by gender, race/ethnicity, BMI and smoking categories. Overall, consistent with the
findings for the whole cohort, we found that higher urinary levels of LMW PAHs biomarkers
were positively associated with high CRP and high total WBC count within these stratified
subgroups. Compared to females, urinary biomarkers of LMW PAH showed stronger
associations with serum CRP and high total WBC count among males. Compared to nonsmokers, urinary biomarkers levels of LMW PAH showed a stronger association with high total
WBC count among current smokers. Some of the odds ratios failed to reach the conventional
levels of statistical significance. P-interaction values for cross-product terms between urinary
OH-PAH levels and stratifying variables were all >0.15 except for gender in the CRP analysis
(P=0.001) and in the WBC analysis (P=0.003).

DISCUSSION
In a multiethnic sample of US adults, we found that higher levels of urinary PAH
biomarkers were positively associated with high serum CRP levels and total WBC count,
independent of surveyed smoking status, serum cotinine and other potential confounders. The
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association was stronger for the low molecular weight PAH biomarkers, compared to 1hydroxypyrene, a urinary metabolite of the higher molecular weight PAH pyrene.
Researchers have examined PAHs directly in the blood and tissues of experimental
animals, and in humans. The most commonly used biomarkers of PAH exposure are urinary
OH-PAH. Urinary OH-PAH has been found to correlate well with levels of exposure to PAHs in
the general population.[24] In addition, there is an evidence that the additional effect of human
occupational exposures can be detected, independent of cigarette smoking.[25]
Humans are usually exposed to PAHs occurring in either a gas or particulate phase.
PAHs with the lower molecular weight (Naphthalene, Fluorene, and Phenanthrene) are more
abundant in the gas phase and are absorbed mainly through inhalation.[58] In contrast, PAHs
with higher molecular weight (Pyrene) have higher vapor pressure and are found in a particulate
form.[58] They can be absorbed through ingestion, skin contact and inhalation.[16, 22]
The mechanisms underlying the positive association of urinary PAH biomarkers with
serum CRP and total WBC count remain unknown. Several in-vitro and animal studies have
reported a positive association between exposure to PAHs and systemic inflammation. [28, 4951] Upon exposure to PAHs, detoxification occurs, leading to the formation of highly reactive
intermediates that can interact with the DNA, forming PAH-DNA plaques in animal arteries. [28,
30] Several studies have suggested that PAHs might exert this atherogenic effect via stimulation
of an inflammatory process involving an increased influx of proinflammatory cells into these
plaques.[49]
Stratifying by gender, the positive association between urinary LMW PAH biomarkers
and serum CRP ≥3 mg/L and total WBC at or above the 95th percentile was found to be stronger
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in males when compared to females, suggesting possible gender differences. It is possible that
hormonal differences in the way in which men and women metabolize PAHs may explain this
observation. PAHs are known to be metabolized by cytochrome P450.[59] It has been shown that
women have increased lung expression of CYP enzymes compared with men which is related to
estrogen.[60, 61] Consequently, accelerated breakdown of PAHs in the lungs may potentiate the
pulmonary response to PAHs in females while reducing the circulating PAH concentrations.[62]
Only two human studies have investigated the association between PAH exposure and
serum inflammatory markers, and the results were inconsistent. In a study of 999 participants
using NHANES 2003–2004, higher exposure to PAHs was associated with elevated levels of
serum CRP.[37] However, in a study of participants in NHANES 2001–2004, urinary levels of
OH-PAH were not associated with other serum inflammatory markers such as total WBC
count.[63] The differences in the results may be partly due to the fact that some NHANES data
on PAHs were withdrawn (and re-released) due to inconsistencies in the laboratory methods used
in 2001-2002 and 2003-2004 data cycles. The re-release of the data provides an important
opportunity for updated analysis. In addition, previous studies included participants with CRP
levels of higher than 10 and total WBC count higher than 12,000 cells/µL, where infection or
autoimmune diseases might have confounding effects. Also adjustment for major confounders
known to interact with inflammatory markers such as alcohol drinking, total cholesterol and
socioeconomic status, and stratifying by major characteristics of the study population were not
performed in these previous studies.
The current study used merged data from NHANES 2001-2002, 2003-2004 and 20052006. The strengths of the study include the relatively large multiethnic sample of the US adults,
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the high quality of NHANES data due to standardized data collection and the ability to adjust for
potential confounders and to stratify by major sociodemographic characteristics. In addition, we
investigated the association of PAH exposure with serum CRP and total WBC count,
independent of the health effects of smoking by adjusting for serum cotinine, an objective
measure of cigarette smoke exposure in addition to stratifying by self-reported smoking status.
Cotinine is the principal metabolite of nicotine. [64] Serum cotinine is considered a more precise
measure of exposure to cigarette smoking when compared to self-reported smoking status, [65,
66] and is considered an accurate biomarker of second-hand smoke exposure. [67]
The study has limitations as well. The cross-sectional nature of NHANES does not allow
us to draw temporal or causal inferences regarding the relationship between PAHs and serum
inflammatory markers. Urinary OH-PAH measurements reflect recent exposure to PAHs and do
not reflect differences between the current exposure sources and the past exposure sources for
each subject. Due to its short half-life, serum cotinine also reflects recent exposure to tobacco
smoke. However, these biases are likely to be non-differential biases, which would minimize any
associations observed.
In conclusion, lower background exposure to PAHs was found to be positively associated
with serum markers of systemic inflammation, i.e. serum CRP and total WBC count independent
of potential confounders. Active smoking appears to play a significant role in the association of
urinary OH-PAH and total WBC count, yet the association persists after adjustment for serum
cotinine and self-reported smoking status. There is a need to replicate these findings in future
prospective studies with adequate sample size.
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Table 1. Baseline characteristics of the study population (20-65 years of age) with measured
urinary levels of OH-PAH and CRP≤ 10mg/L
Mean values (Std error of mean) or
Characteristics
Sample size (weighted percentages)
Female (%)
1136 (47.7)
Age (years)
40.9 (0.34)
Race/Ethnicity (%)
Non-Hispanic Whites
1200 (72.9)
Non-Hispanic Blacks
463 (10.0)
Others
691 (17.1)
Education categories (%)
Less than high school
547 (14.2%)
High school
541 (24.2)
Above high school
1266 (61.6)
Below poverty level (%)
392 (12.1)
Smoking categories (%)
Never
1229 (50.5)
Former smokers
501 (21.7)
Current smokers
624 (27.8)
Alcohol drinking (%)
Yes
1731 (77.2)
Body mass index (%)
Normal weight (<25.0 kg/m2)
784 (36.5)
Overweight (25.0-29.9 kg/m2)
827 (32.9)
2
Obese (>30.0 kg/m )
743 (30.6)
Serum cotinine (ng/mL)
74.2 (4.25)
Total cholesterol (mg/dL)
201.6 (1.43)
Systolic blood pressure (mmHg)
119.1 (0.47)
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis with serum CRP levels ≤ 10mg/L
Chemicals
Selected percentiles
th
th
Sample
Mean
Minimum
10
25
50th
75th
90th
Maximum
size
1- Hydroxynaphthalene
2-Hydroxynaphthalene

2480
2488

44914
6235.5

50.8
93.5

502.6
795.9

843.7
1341.8

2009.3
2820.7

7116.1
7947.9

17899
16009

39226536
404573

2-Hydroxyfluorene
3-Hydroxyfluorene

2465
2450

654.4
339.0

2.2
1.2

102.4
34.5

143.3
52.5

247.8
97.6

751.2
407.4

1756.9
1014.8

29914
19084

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2469
2448
2444

215.31
96.6
191.5

0.7
0.5
0.7

60.8
22.3
37.7

89.3
35.1
55.4

139.7
56.9
91.8

232.7
99.9
176.2

371.3
177.1
342.0

8341.9
5069.4
20248

1-Hydroxypyrene

2461

136.5

0.9

22.3

35.5

66.1

136.6

272.7

10014

Summed LMW PAH biomarkers

2369

54230

620.0

2119.5

3156.6

6140.5

18777

38131

39235478
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Table 3: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis with total WBC count between
4000-12,000 cells/µL
Chemicals and blood markers
Selected percentiles
th
th
Sample Mean
Minimum
10
25
50th
75th
90th
Maximum
size
1-Hydroxynaphthalene
2-Hydroxynaphthalene

2620
2628

43340
6156.1

50.8
9.2

485.6
796.5

825.2
1357.5

1963.4
2825.1

6878.0
7829.2

17816
15544

39226536
404573

2-Hydroxyfluorene
3-Hydroxyfluorene

2604
2588

632.8
325.5

2.2
1.2

102.8
34.3

143.4
52.3

244.4
95.7

735.1
377.7

1687.9
950.2

29914
19084

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2610
2587
2585

213.2
96.3
189.1

0.7
0.5
0.7

60.9
22.7
37.5

89.7
35.7
54.9

140.4
58.3
90.0

229.3
101.2
170.6

366.9
177.3
331.0

8341.9
5069.4
20248

1-Hydroxypyrene

2600

133.9

0.9

22.5

35.4

65.4

132.0

267.3

10014

Summed LMW PAH biomarkers

2505

52480

508.7

2122.4

6085.4

18255

18255

37021

39235478
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Table 4: Weighted Pearson correlations between log-transformed urinary levels OH-PAH (ng/g creatinine).
Chemicals
1-NAP*
2- NAP*
2-FLUO+
3-FLUO+
1-PHENᵟ
2-PHENᵟ

3-PHENᵟ

1-PYRŷ

1- Hydroxynaphthalene
2- Hydroxynaphthalene

1
-----

0.60
1

0.61
0.71

0.62
0.71

0.43
0.43

0.41
0.48

0.48
0.53

0.49
0.57

2-Hydroxyfluorene
3-Hydroxyfluorene

---------

---------

1
-----

0.93
1

0.66
0.60

0.68
0.62

0.75
0.73

0.73
0.71

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

-------------

-------------

-------------

-------------

1
---------

0.76
1
-----

0.78
0.76
1

0.72
0.71
0.72

1-Hydroxypyrene
------------* NAP= Hydroxynaphthalene + FLUO= Hydroxyfluorene

----------------1
ᵟ PHEN= Hydroxyphenanthrene
ŷ PYR = Hydroxypyrene
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Table 5: Linear regression: Association of urinary OH-PAH levels (ng/g creatinine) and serum CRP (mg/L).
Chemicals
Sample size
Log OH-PAH
Age-sex adjusted change in CRP +
2480
0.04(-0.03, 0.11)
1- Hydroxynaphthalene
2488
0.15(0.04, 0.26)
2-Hydroxynaphthalene

Log OH-PAH
Multivariable change in CRP *
0.07(-0.01, 0.14)
0.14(0.04, 0.25)

2-Hydroxyfluorene
3-Hydroxyfluorene

2465
2450

0.14(0.05, 0.24)
0.07(0.00, 0.14)

0.16(0.06, 0.26)
0.10(0.02, 0.18)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2469
2448
2444

0.20(0.07, 0.32)
0.24(0.05, 0.43)
0.02(-0.11, 0.15)

0.21(0.10, 0.33)
0.19(0.01, 0.36)
0.05(-0.06, 0.17)

1-Hydroxypyrene

2461

0.11(0.001, 0.22)

0.11(-0.004, 0.21)

2369
0.13(0.02, 0.23)
0.15(0.04, 0.25)
Summed LMW PAH biomarkers
+
Adjusted for age (years) and sex (Male/ Female).
* Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all
others), alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and
systolic blood pressure (mm Hg).
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Table 6: Linear regression: Association of urinary OH-PAH levels (ng/g creatinine) and total WBC count (cells/uL).
Chemicals
Sample size
Log OH-PAH
Log OH-PAH
+
Age-sex adjusted change in WBC
Multivariable change in WBC *
2620
176.1(108.8, 243.4)
89.7(8.9, 170.5)
1- Hydroxynaphthalene
2628
345.5(233.4, 457.6)
229.2(103.2, 355.3)
2-Hydroxynaphthalene
2-Hydroxyfluorene
3-Hydroxyfluorene

2604
2588

396.2(310.8, 481.5)
305.8(237.5, 347.1)

310.1(190.1, 430.0)
235.9(135.9, 335.9)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2610
2587
2585

206.9(110.8, 503.0)
354.7(258.1, 451.3)
308.0(204.3, 411.7)

132.4(19.5, 245.3)
213.6(117.3, 309.9)
199.8(81.8, 317.7)

1-Hydroxypyrene

2600

283.5(201.4, 365.6)

144.5(53.8, 235.2)

2505
296.4(202.3, 390.44)
186.0(73.0, 299.0)
Summed LMW PAH biomarkers
+
Adjusted for age (years) and sex (Male/ Female).
* Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all
others), alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and
systolic blood pressure (mm Hg).
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Table 7. Logistic regression: Association of urinary OH-PAH levels (ng/g creatinine) and CRP ≥3mg/L
Chemicals
Sample size
Quartile 1
Quartile 2
Quartile 3
Multivariable odds ratio (95% confidence interval)*

Quartile 4

Log-PAH

1-Hydroxynaphthalene
2-Hydroxynaphthalene

2480
2488

1 (Referent)
1 (Referent)

0.94(0.69, 1.28)
1.10(0.80, 1.51)

1.07(0.75, 1.52)
1.22(0.81, 1.82)

1.53(1.01, 2.32)
1.66(1.10, 2.48)

1.08(0.98, 1.20)
1.15(1.01, 1.32)

2-Hydroxyfluorene
3-Hydroxyfluorene

2465
2450

1 (Referent)
1 (Referent)

1.09(0.79, 1.50)
0.97(0.72, 1.31)

1.34(0.95, 1.89)
1.17(0.87, 1.59)

1.63(1.14, 2.33)
1.58(1.15, 2.16)

1.22(1.09, 1.37)
1.14(1.03, 1.25)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2469
2448
2444

1 (Referent)
1 (Referent)
1 (Referent)

1.45(1.00, 2.12)
1.23(0.74, 2.05)
1.01(0.71, 1.43)

1.84(1.38, 2.46)
1.58(1.00, 2.51)
1.03(0.76, 1.40)

1.67(1.25, 2.22)
1.88(1.26, 2.80)
1.21(0.90, 1.64)

1.23(1.09, 1.40)
1.25(1.01, 1.54)
1.09(0.96, 1.24)

1-Hydroxypyrene

2461

1 (Referent)

1.24(0.86, 1.78)

1.41(1.09, 1.81)

1.38(0.92, 1.95)

1.14(1.01, 1.29)

2369
1 (referent)
1.09(0.73, 1.61)
1.18(0.80, 1.75) 1.77(1.13, 2.76) 1.16(1.03, 1.31)
Summed LMW PAH biomarkers
*Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all others),
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and systolic
blood pressure (mm Hg).
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Table 8. Logistic regression: Association of urinary OH-PAH levels (ng/g creatinine) and high total WBC count (cells/uL) at or above the 95th
percentile of the total WBC distribution
Chemicals
Sample size Quartile 1
Quartile 2
Quartile 3
Quartile 4
Log-PAH
Multivariable odds ratio (95% confidence interval)*
1-Hydroxynaphthalene
2-Hydroxynaphthalene

2620
2628

1 (Referent)
1 (Referent)

1.44(0.78, 2.64)
0.70(0.30, 1.59)

1.20(0.60, 2.39)
0.98(0.49, 1.97)

2.18(1.17, 4.05)
2.58(1.05, 6.35)

1.18(1.02, 1.37)
1.33(0.87, 2.03)

2-Hydroxyfluorene
3-Hydroxyfluorene

2604
2588

1 (Referent)
1 (Referent)

1.02(0.44, 2.36)
1.34(0.62, 2.89)

1.63(0.86, 3.08)
1.90(0.93, 3.87)

3.07(1.47, 6.43)
4.15(1.93, 8.92)

1.50(1.17, 1.92)
1.42(1.14, 1.78)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2610
2587
2585

1 (Referent)
1 (Referent)
1 (Referent)

1.04(0.51, 2.13)
1.94(0.89, 4.23)
1.55(0.85, 2.83)

1.67(0.90, 3.10)
1.45(0.69, 3.04)
1.19(0.64, 2.20)

1.52(0.77, 3.02)
2.25(1.07, 4.75)
1.86(0.92, 3.76)

1.20(0.91, 1.58)
1.32(1.03, 1.70)
1.27(0.99, 1.64)

1-Hydroxypyrene

2600

1 (Referent)

1.68(0.80, 3.55)

1.94(0.98, 3.82)

2.27(1.12, 4.61)

1.31(1.03, 1.66)

Summed LMW PAH
2505
1 (Referent)
0.98(0.51, 1.90)
1.03(0.59, 1.80)
2.57(1.27, 5.19) 1.34(1.12, 1.60)
Biomarkers
*Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all others),
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and systolic
blood pressure (mm Hg).
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Table 9. Logistic regression: Association of summed urinary biomarkers of LMW PAHs (ng/g creatinine) and serum inflammatory markers by
sociodemographic characteristics
Subgroups
Multivariable odds ratio of CRP
P interaction
Multivariable odds ratio of total WBC count in
p-interaction
≥3mg/L*
the 95th percentile*
Gender*
Female
Male
Race-ethnicity*
Non-Hispanic white
All others
Body mass index+
Non obese
Obese

0.001
1.08(0.93, 1.25)
1.32(1.12, 1.55)

0.003
1.21(0.95, 1.55)
1.90(1.41, 2.56)

0.29
1.16(1.00, 1.34)
1.18(0.98, 1.41)

0.29
1.34(1.10, 1.64)
1.27(0.92, 1.74)

0.55
1.20(1.01, 1.41)
1.08(0.91, 1.27)

0.71
1.39(1.11, 1.75)
1.28(1.00, 1.64)

0.27
0.35
Smoking*
1.21(0.98, 1.50)
1.21(0.88, 1.68)
Never smokers
1.03(0.88, 1.19)
1.15(0.83, 1.59)
Former smokers
1.10(0.81,
1.49)
1.78(1.28, 2.48)
Current smokers
* Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic white, non-Hispanic black, all others), poverty-income ratio, alcohol drinking
(yes/no), diabetes (absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure
(mm Hg), except for stratified variables.
+ Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic white, non-Hispanic black, all others), poverty-income ratio, alcohol drinking
(yes/no), diabetes (absent/present), BMI (Kg/m2), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg),
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CHAPTER 2
The Association of Urinary Polycyclic Aromatic Hydrocarbon Biomarkers and Diabetes
Mellitus.
Abstract
Diabetes mellitus is a major cause of morbidity and mortality in the United States. Recent
evidences has suggested that common environmental exposures affecting large sections of the
population may be a determinant of diabetes risk. Polycyclic aromatic hydrocarbons (PAHs) are
a group of compounds produced as byproducts of incomplete combustion of organic materials.
Animal studies have reported a positive association between PAHs and inflammation, and
subsequent development of diabetes mellitus. Occupational studies have suggested that exposure
to other aromatic hydrocarbons such as Dioxins, a group of halogenated aromatic hydrocarbons,
may be associated with diabetes mellitus risk in humans. In the current study we investigate
whether background exposure to PAHs is associated with increased risk of diabetes mellitus in
the general population. We examined participants from the merged National Health and
Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our exposures of interest
were eight urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAH) and our outcome
was diabetes mellitus defined as a serum glucose ≥126mg/dL after fasting for a minimum of 8
hours, glycosylated hemoglobin level ≥ 6.5%, a self-reported physician-diagnosed diabetes, or
current use of oral hypoglycemic medication or insulin. Compared to participants with summed
urinary biomarkers of LMW PAHs in the lowest quartile, the multivariable odds ratio (95%
confidence interval) of diabetes mellitus among those in the highest quartile was 2.79 (1.46,
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5.32). In addition, urinary levels of 2-hydroxynapthalene, 2-hyrdroxyfluorene, and 2hydroxyphenanthrene showed statistically significant associations with fasting blood glucose
(mg/dl) and glycosylated hemoglobin (%), independent of potential confounders. Levels of 1hydroxypyrene, the urinary biomarker of the higher molecular weight PAH pyrene, showed a
less strong association with diabetes mellitus.
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Diabetes mellitus is the seventh leading cause of death in the US.[30] Approximately
8.3% of the American population has diabetes.[30] Diabetes is a major risk factor for
cardiovascular disease, kidney failure, non-traumatic lower limb amputations, and retinopathy
among adults in the US.[2, 3] Recent studies have suggested that common environmental
exposures affecting large sections of the population may be a determinant of diabetes risk.[13]
Polycyclic aromatic hydrocarbons (PAHs) are a group of atmospheric pollutants
composed of aromatic rings.[16, 21, 45] Major sources of PAHs include coal, oil, tar, cigarette
smoking and grilled/smoked food.[47, 48, 68] PAHs are usually found in gaseous or particulate
form. Low molecular weight (LMW) PAHs (naphthalene, Fluorene and Phenanthrene) are
usually found in gaseous form in the ambient air where they are absorbed by inhalation. Higher
molecular weight PAHs (pyrene) are usually found in particulate form where they can be
ingested, inhaled or absorbed through the skin.[22, 69]
Several in-vitro and animal studies have reported a positive association between exposure
to PAHs, and inflammation with subsequent development of diabetes mellitus.[70] In addition,
several studies have suggested that exposure to other aromatic hydrocarbons such as Dioxins, a
group of halogenated aromatic hydrocarbons is associated with diabetes mellitus in humans.[14]
However, there are no studies investigating the association of lower background exposure to
PAHs with diabetes mellitus in the general population independent of smoking, a major source
of PAHs.
In this context, we examined the association between eight urinary monohydroxy-PAH
(OH-PAH) and diabetes mellitus in a nationally representative sample of United States (US)
adults after adjusting for age, gender, race/ethnicity, body mass index(BMI), serum cotinine,
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self-reported smoking status and other potential confounders. Because metabolism and health
effects of exposure to PAHs mixtures were found to be different from that of exposure to
individual PAHs [39] , we created a summed LMW PAH biomarker variable, indicating a
graduating level of exposure to multiple LMW PAHs simultaneously.

METHODS

Study population

The present study is based on merged data from the 2001-2002, 2003-2004 and 2005-2006
National Health and Nutrition Examination Survey (NHANES). NHANES surveys were
designed to be nationally representative of the non-institutionalized U.S. civilian population by
using a complex stratified multistage probability sample.[71] Selection was based on counties,
blocks, households and individuals within households, and included oversampling of nonHispanic Blacks and Mexican Americans in order to provide stable estimates of these groups.
Data were collected from interviews, questionnaire, examinations, and laboratory tests of
biological samples. The data have been released for public use in two-year increments since
1999.

Out of 31,509 participants in NHANES 2001-2006, there were 3326 participants, 20-65 years
of age with measured levels of urinary PAH biomarkers. We excluded participants with missing
information on serum cotinine level or other variables included in the multivariable model. This
resulted in 2661 participants included in the additive LMW PAH-diabetes analyses. We excluded
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those on oral hypoglycemic medications or insulin to avoid the confounding effect of
antidiabetic medications, resulting in 2583 participants included in the added PAH biomarkersHbA1c analysis and 1275 participants included in the added PAH biomarkers- fasting blood
glucose analyses

Main outcome of interest: Diabetes mellitus

Plasma glucose concentration was determined by a hexokinase method. One-half of the
NHANES participants were sampled to attend the morning session. Those participants ages 12
and older appointed to attend the morning session were instructed to fast at least 9 hours prior to
their appointment time. Glycohemoglobin measurements for NHANES 2001-2002 and 20032004 were performed by the Diabetes Diagnostic Laboratory at the University of MissouriColumbia using Primus CLC330 and Primus CLC 385 (Primus Corporation, Kansas City, MO).
Glycohemoglobin measurements for NHANES 2005-2006 were performed by the Diabetes
Laboratory at the University of Minnesota using Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer
(Tosoh Medics, Inc., San Francisco, CA). Both assays use a High Performance Liquid
Chromatography (HPLC) system.
Diabetes was defined based on the guidelines of the American Diabetes Association as a
serum glucose ≥126mg/dL after fasting for a minimum of 8 hours, glycosylated hemoglobin
level ≥ 6.5% a self-reported physician-diagnosed diabetes, or current use of oral hypoglycemic
medication or insulin.[72]
Main exposure: Urinary levels of monohydroxy-PAH
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Urine specimens are processed, stored, and shipped to the Division of Environmental
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease
Control and Prevention for analysis. The specific analytes measured in this method are
monohydroxy-PAH (OH-PAH). By evaluating these analytes in urine, a measurement of the
body burden from PAH exposure is obtained. The procedure involves enzymatic hydrolysis of
urine, extraction, derivatization and analysis using capillary gas chromatography combined with
high resolution mass spectrometry (GC-HRMS). Detailed specimen collection and processing
instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures
Manual (LPM).
Eight urinary OH-PAH analytes, 1- hydroxynaphthalene, 2- hydroxynaphthalene, 2hydroxyfluorene, 3-hrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3hydroxyphenanthrene and 1-hydroxypyrene, are consistently available in NHANES 2001-2006.
All analytes were measured in the same unit, ng/L. Urinary OH-PAH were corrected for
creatinine concentration, a urinary marker of kidney function to adjust for urinary dilution [56].
Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine level (mg/dL) multiplied
by 0.01 i.e.; [(ng/L) ÷ (mg/dL*0.01)], and expressed as nanogram per gram of creatinine (ng/g
creatinine).
Exposure measurements
Information on age, gender, race/ethnicity, alcohol intake, income and cigarette smoking
were obtained from a standardized questionnaire during a home interview. Alcohol consumption
was categorized into none and alcohol drinker. Income-poverty ratio was used as a measure of
the socioeconomic status. The Department of Health and Human Services’ poverty guidelines
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were used as the poverty measure to calculate this ratio. Smoking status was categorized into
never smokers (smoked <100 cigarettes during their lifetime), former smokers (smoked ⩾100
cigarettes during their lifetime and currently not smoking), current smokers (smoked ⩾100
cigarettes during their lifetime and currently smoking). Information on anthropometric, physical
and laboratory components were obtained during the medical examination center examination.
Body mass index was calculated as weight in kilograms divided by height in meters squared.
Seated blood pressure was measured using a mercury sphygmomanometer according to the
American Heart Association and JNC7 recommendations.[57] Up to 3 measurements were
averaged for blood pressure. Total cholesterol was measured enzymatically. Serum cotinine was
measured by isotope dilution-high performance liquid chromatography atmospheric pressure
chemical ionization tandem mass spectrometry (ID HPLC-APCI MS/MS).
Statistical analysis
Urinary levels of OH-PAH were analyzed both as continuous as well as categorical
variables. For analysis as continuous variables, urinary levels of OH-PAH were log-transformed
as a result of their skewed distribution. We created a summed LMW PAH variable by adding the
urinary levels of the LMW PAHs (naphthalene, fluorene and phenanthrene).
We ran linear regression models to calculate the multivariable change and 95%
confidence interval (CI) in HbA1c (%) and fasting plasma glucose (mg/dl) for increasing urinary
OH-PAH levels. In addition, we ran logistic regression models to calculate the multivariable
odds ratio (OR) and 95% confidence interval (CI) of diabetes mellitus, for each higher urinary
OH-PAH quartile by using the lowest quartile as the referent. Variables were included in the
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model if they satisfied two conditions: first, a plausible association with the main outcome that is
not causal, and second, if the percent change of the odds ratio after adjusting for the potential
confounder was over 10 %. Accordingly, final models were adjusted for age (years), sex (men,
women), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio,
alcohol drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum
cotinine (ng/mL) and systolic blood pressure (mm Hg).
To further ensure that the association was parallel for subgroups, we performed subgroup
analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that account
for the unequal probabilities of selection, oversampling, and nonresponse in the NHANES
survey were applied for all analyses. Analyses were conducted using SAS (version 9.3, SAS
Institute, Cary, NC) software. Standard errors were estimated using the Taylor series
linearization method.

RESULTS
Table 1 presents the baseline characteristics of the study population. The study
population was primarily non-Hispanic White (72.2%). Normal weight, overweight, and obese
BMI categories were equally distributed. Approximately one-half (50.5%) were never smokers,
and the remainder was former smokers (21.5%) and current smokers (26.0%). The mean of
serum cotinine level was 74.4 ng/mL. Diabetes was reported in 7.8 % of the population. Table 2
presents the sample sizes, weighted means and weighted percentile of urinary levels of OH-PAH
used in the final analysis.
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Table 3 presents the results of the analyses examining the linear association between
urinary OH-PAH, and HbA1c (%). Urinary levels of OH-PAH were positively associated with
HbA1c levels in the multivariable adjusted model; however, 1- hydroxynaphthalene, 1hydroxypyrene and summed LMW PAH biomarkers were not statistically significant. Table 4
presents the results of the analyses examining the linear association between urinary OH-PAH
and fasting plasma glucose (mg/dl). Urinary levels of OH-PAH were positively associated with
fasting blood glucose; however, only 2-hydroxynapthalene, 2-hrdroxyfluorene, 2hydroxyphenanthrene and 1-hydroxypyene were statistically significant.
Table 5 presents the odds ratio of the association between urinary levels of OH- PAH and
diabetes mellitus. Overall, urinary levels of OH-PAH were positively associated with diabetes
mellitus in the multivariable adjusted models. Using urinary OH-PAH levels as continuous
variables, the observed associations were still positive. Although positive, the associations
between urinary 1-hydroxyphenanthrene and 1-hydroxypyrene and diabetes were not statistically
significant.
Next, to examine confounding, we performed subgroup analyses by gender,
race/ethnicity, BMI and smoking categories (Table 6). Overall, higher summed levels of LMW
PAH biomarkers were positively associated with diabetes within the stratified subgroups.
Although positive, some of the odds ratio failed to reach the statistical significance. P-interaction
values for cross-product terms between urinary OH-PAH levels and stratifying variables were all
>0.10 except for BMI (P=0.03). Urinary 1-hydroxypyrene levels showed a less strong
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association with diabetes mellitus within the stratified subgroups when compared to LMW
PAHs.
DISCUSSION
In a relatively large multiethnic sample of US adults, we found that higher levels of
urinary biomarkers of LMW PAHs were positively associated diabetes mellitus, independent of
potential confounders. In addition, urinary levels of 2-hydroxynapthalene, 2-hrdroxyfluorene,
and 2-hydroxyphenanthrene showed positive associations with glycosylated hemoglobin and
fasting plasma glucose in the multivariable adjusted model. In subsequent subgroup analyses, the
positive association was present within subgroups of gender, race, BMI and smoking status.
Urinary biomarker levels of the higher molecular weight pyrene showed a less strong association
with diabetes mellitus. Since LMW PAHs are usually found in gaseous form, absorption of
PAHs through inhalation from the ambient air may exert the greatest effect on the association
between PAHs and diabetes when compared to the higher molecular weight PAHs.
Researchers have examined PAHs directly in the blood and tissues of experimental
animals; however, these methods have not been widely used in humans due to the high costs and
the limited clinical significance of testing. The most commonly used biomarkers of PAH
exposure are urinary OH-PAH biomarkers and PAH-DNA adducts. Urinary OH-PAH
biomarkers and, to a lesser extent, PAH-DNA adducts have been found to correlate well with
low background levels of exposure to PAHs.[24]
The mechanisms underlying the positive association between urinary PAH biomarkers
and diabetes remain unknown. Several in-vitro and animal studies have reported a positive
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association between exposure to PAHs and subsequent development of oxidative stress.[28]
Increasing evidence suggests that oxidative stress plays a major role in the pathogenesis of
diabetes mellitus.[73] Animal studies have reported a positive association between PAH
exposure and inflammation.[49] In addition, higher exposure to PAHs was associated with
elevated levels of C-reactive protein, a serum inflammatory marker in humans.[37] Inflammation
has been found to strongly associate with insulin resistance and diabetes mellitus.[74, 75]
Moreover, chronic exposure to PAHs was found to cause intestinal inflammation with
subsequent increase in the risk of type 2 diabetes in animals.[70] Besides its suggested
inflammatory effects, several studies suggested that PAHs may cause disruption of the endocrine
system, with changes in plasma estrogen concentrations in rats upon exposure to PAHs.[32]
Exposure to PAHs was suggested as a predisposing factor in the etiology of breast cancer by
disrupting the expression of BRCA-1 transcription in estrogen receptor-positive tumors.[76] In
the same context, women with a BRCA-1 mutation were found to have a 2-fold increase in the
risk of developing diabetes.[77]
The current study has strengths including the relatively large multiethnic sample of US
adults, the high quality of NHANES laboratory and data collection methods and the ability to
adjust for potential confounders. In addition, this is the first study to investigate the association
between PAHs and diabetes in humans adjusting for potential confounders including serum
cotinine, an objective measure of cigarette smoke exposure. Serum cotinine is considered a more
precise measure of exposure to cigarette smoking when compared to self-reported smoking
status[65, 66] and is considered an accurate biomarker of SHS exposure.[67]
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The study has several limitations. The cross-sectional nature of NHANES does not allow
us to draw temporal or causal inferences regarding the relationship between PAHs and diabetes
mellitus. Urinary PAH measurements reflect recent exposure if there are great differences
between the current exposure sources and the past exposure sources for each subject. However,
these biases are likely to be non-differential biases, which would minimize any associations
observed. In addition, because NHANES does not collect information to identify the type of
diabetes, we cannot not distinguish type 1 and type 2 diabetes. However, we believe that the
majority of diabetes subjects in our sample have type 2 diabetes mellitus.
In conclusion, urinary biomarker levels of LMW PAHs were found to be positively
associated with diabetes mellitus, independent of potential confounders. Both PAH exposure and
diabetes mellitus are highly prevalent in the United States. Considering the limitations of our
study, further prospective studies are necessary to determine the causal relationship between
PAH exposure and the risk of diabetes mellitus.
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Table 1. Baseline characteristics of the study population 20-65 years of age with measured
urinary levels of OH-PAH (n=2661)
Mean values ± (Std error of mean) or
Characteristics
Sample size (weighted percentages)
Female (%)
1354 (49.6)
Age (years)
41.0 ± (0.32)
Race/Ethnicity (%)
Non-Hispanic Whites
1332 (72.2)
Non-Hispanic Blacks
551 (10.6)
Others
778 (17.3)
Education categories (%)
Less than high school
637 (14.4)
High school
619 (24.7)
Above high school
1405 (60.9)
Below poverty level (%)
461 (12.6)
Smoking categories (%)
Never
1395 (50.5)
Former smokers
559 (21.5)
Current smokers
707 (26.0)
Alcohol drinking (%)
No
742 (23.7)
Yes
1919 (76.3)
Body mass index (%)
Normal weight (<25.0 kg/m2)
824 (34.3)
Overweight (25.0-29.9 kg/m2)
901 (31.8)
2
Obese (>3vSZ0.0 kg/m )
936 (33.9)
Serum cotinine (ng/mL)
74.4 ± (3.84)
Total cholesterol (mg/dL)
201.3 ± (1.33)
Systolic blood pressure (mmHg)
119.3± (0.47)
Diabetes (%)
254(7.8)
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis
Chemicals
Selected percentiles
th
th
Sample
Mean
Minimum
10
25
50th
75th
size

90th

Maximum

1- Hydroxynaphthalene
2-Hydroxynaphthalene

2785
2794

41708
6263.3

50.8
9.2

488.7
798.4

832.6
1356.5

1996.3
2885.2

7120.0
7952.5

17952
16001

39226536
404573

2-Hydroxyfluorene
3-Hydroxyfluorene

2767
2751

651.3
334.5

2.2
1.2

102.8
34.4

144.0
52.3

245.6
96.7

752.1
400.7

1740.4
1004.8

29914
19084

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2773
2747
2745

214.1
96.6
188.5

0.7
0.5
0.7

60.8
22.7
37.6

89.4
35.7
55.0

140.9
58.4
90.7

234.6
101.7
173.8

370.2
178.4
333.7

8341.9
5069.4
20248

1-Hydroxypyrene

2764

134.4

0.9

22.5

35.8

65.9

136.6

270.4

10014

Summed LMW PAH biomarkers

2661

50970

508.8

2131.3

3180.1

6207.5

18772

38592

39235478
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Table 3 Linear regression: Association of urinary OH-PAH (ng/g creatinine) and HbA1c (%)
Chemicals
Sample size
Age-sex adjusted change (95% C.I)
in HbA1c+

Multivariable adjusted change (95% C.I)
in HbA1c*

1-Hydroxynaphthalene
2-Hydroxynaphthalene

2707
2715

-0.01(-0.03, 0.01)
0.02(-0.003, 0.40)

0.01(-0.01, 0.03)
0.03(0.004, 0.06)

2-Hydroxyfluorene
3-Hydroxyfluorene

2688
2672

0.01(-0.01, 0.04)
0.004(-0.01, 0.03)

0.05(0.02, 0.09)
0.04(0.01, 0.07)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2694
2668
2643

0.02(-0.03, 0.06)
0.05(0.02, 0.08)
0.02(-0.01, 0.05)

0.05(0.002, 0.10)
0.06(0.02, 0.10)
0.05(0.01, 0.09)

1-Hydroxypyrene

2685

0.01(-0.02, 0.04)

0.03(-0.01, 0.06)

2583
0.00(-0.02, 0.02)
0.01(-0.01, 0.04)
Summed LMW PAH biomarkers
*Adjusted for age (years), sex (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty income ratio, alcohol
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg).
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Table 4 Linear regression: Association of urinary OH-PAH (ng/g creatinine) and fasting glucose levels (mg/dL)
Chemicals
Sample size
Age-sex adjusted change (95% C.I) in
Multivariable adjusted change (95% C.I) in
fasting glucose+
fasting glucose*
1-Hydroxynaphthalene
2-Hydroxynaphthalene

1339
1342

-0.08(-0.92, 0.77)
1.11(0.10, 2.11)

0.50(-0.66, 1.65)
1.95(0.26, 3.63)

2-Hydroxyfluorene
3-Hydroxyfluorene

1325
1316

0.87(-0.45, 2.19)
0.29(-0.83, 1.41)

2.50(0.28, 4.72)
1.75(-0.16, 3.65)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

1326
1317
1314

2.14(-0.57, 4.84)
2.49(0.50, 4.47)
0.95(-0.94, 2.83)

2.88(-0.11, 5.87)
2.82(0.53, 5.11)
2.15(-0.29, 4.59)

1-Hydroxypyrene

1322

1.34(-0.36, 3.04)

2.15(0.01, 4.30)

1275
0.27(-0.82, 1.36)
1.16(-0.50, 2.83)
Summed LMW PAH biomarkers
*Adjusted for age (years), sex (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty income ratio, alcohol
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg).
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Table 5: Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and diabetes mellitus
Chemicals
Sample
Quartile 1
Quartile 2
Quartile 3
size
Multivariable odds ratio (95% confidence interval)*

Quartile 4

PTrend

Log-PAH

1- Hydroxynaphthalene
2-Hydroxynaphthalene

2785
2794

1 (Referent)
1 (Referent)

1.40(0.80, 1.05)
2.70(1.55, 4.69)

1.65(0.99, 2.75)
1.85(1.05, 3.24)

3.04(1.50, 6.17)
3.25(1.75, 6.04)

0.003
0.002

1.19(1.02, 1.39)
1.40(1.14, 1.72)

2-Hydroxyfluorene
3-Hydroxyfluorene

2767
2751

1 (Referent)
1 (Referent)

0.71(0.43, 1.17)
0.77(0.47, 1.26)

1.03(0.64, 1.67)
1.09(0.71, 1.70)

1.37(0.81, 2.31)
1.49(0.84, 2.66)

0.13
0.09

1.22(1.02, 1.47)
1.08(0.92, 1.26)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2773
2747
2745

1 (Referent)
1 (Referent)
1 (Referent)

1.39(0.83, 2.33)
1.00(0.60, 1.68)
1.00(0.65, 1.52)

1.25(0.69, 2.25)
1.26(0.82, 1.94)
1.27(0.84, 1.91)

1.43(0.86, 2.37)
1.87(1.13, 3.10)
1.28(0.85, 1.94)

0.24
0.005
0.12

1.14(0.93, 1.41)
1.26(1.06, 1.51)
1.21(1.01, 1.44)

1-Hydroxypyrene

2764

1 (Referent)

1.53(0.85, 2.72)

1.83(0.99, 3.39)

1.68(1.00, 2.83)

0.03

1.14(0.96, 1.35)

Summed LMW PAH
2661
1 (referent)
1.67(0.97, 2.90)
1.91(1.19, 3.07) 2.79(1.46, 5.32)
0.002 1.26(1.02, 1.56)
biomarkers
*Adjusted for age (years), sex (male, female), BMI (normal weight, overweight, obese), race (non-Hispanic White, non-Hispanic Black, all others),
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg).

45

Table 6. Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and diabetes mellitus by sociodemographic characteristics
Subgroups

Summed urinary levels LMW PAH biomarkers
Multivariable odds ratio of diabetes
mellitus

p-interaction

1-hydroxypyrene
Multivariable odds ratio of diabetes
mellitus

0.51

Gender*
Female
Male

1.22(0.92, 1.62)
1.38(1.07, 1.78)

Race-ethnicity*
Non-Hispanic White
All others

1.27(1.00, 1.63)
1.19(0.90, 1.56)

Body mass index+
Non Obese
Obese

1.18(0.85, 1.64)
1.26(0.96, 1.66)

p-interaction
0.27

0.97(0.73, 1.27)
1.26(1.002, 1.58)
0.97

0.45
1.13(0.91, 1.40)
1.18(0.94, 1.48)

0.03

0.19
1.20(0.98, 1.48)
1.05(0.81, 1.37)

0.73
0.33
Smoking*
1.26(1.01,
1.56)
0.99(0.77,
1.28)
Never smokers
1.14(0.88, 1.49)
1.32(1.00, 1.75)
Former smokers
1.63(0.96, 2.79)
1.36(0.93, 1.99)
Current smokers
* Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg),
except for stratified variables.
+
Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol
drinking (yes/no), BMI (Kg/m2), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg), except for stratified
variables.
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CHAPTER 3
The Association of Urinary Polycyclic Aromatic Hydrocarbon Biomarkers and
Cardiovascular Disease.

Abstract
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants produced by
incomplete combustion of organic materials. Several animal studies have reported a positive
association of PAHs with oxidative stress, inflammation and subsequent development of
atherosclerosis, a major underlying risk factor for cardiovascular disease (CVD). In addition,
several occupational studies have reported positive associations between PAH exposure and
CVD morbidity and mortality. However, it is not clear if lower background exposure to PAHs in
the general population is associated with CVD. We examined participants from the merged
National Health and Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our
exposures of interest were eight urinary monohydroxy polycyclic aromatic hydrocarbons (OHPAH) and our outcomes were self-reported CVD. Urinary levels of PAH biomarkers were
positively associated with CVD, however only 1-hydroxynapthalene and additive biomarkers of
low molecular weight (LMW) PAHs were statistically significant. Compared to those with
summed urinary biomarkers of LMW PAHs in the lowest quartile, the multivariable odds ratio
(95% confidence interval) of self-reported CVD among those in the highest quartile was
2.27(1.03, 5.02). Levels of 1-hydroxypyrene, the urinary biomarker of the higher molecular
weight PAH pyrene, also showed a significant positive association with CVD. In subsequent
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subgroup analyses, the positive association was found to be present in subgroups of gender,
race/ethnicity, body mass index and smoking status. This study suggested that background
exposure to PAHs was positively associated with self-reported CVD in the U.S. general
population. Further prospective studies with adequate sample size are needed to replicate or
refute our findings.
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Despite advances in prevention, diagnosis and treatment, cardiovascular disease (CVD)
remains the number one cause of mortality in United States adults.[1] From a public health point
of view, identifying novel risk factors for CVD is therefore important. Recent epidemiological
evidence suggests that exposure to particulate matter present in ambient air is associated with
increased CVD risk.[78, 79] In addition, there is increasing evidence that smaller particles and
gases may pose a greater CVD risk possibly through development of atherosclerosis.[80]
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants that occur in
oil, coal, and tar deposits, and are produced as byproducts of smoking, indoors and outdoors fuel
burning and food grilling.[18, 46-48] Active smoking and second-hand smoke (SHS) exposure
are major sources of PAHs. PAHs are predominantly found in gaseous or particulate form. Low
molecular weight (LMW) PAHs are abundant in gaseous form in the ambient air and are usually
absorbed into the human body through inhalation. The higher molecular weight PAHs are
usually found in particulate form and therefore, can be ingested, inhaled or absorbed through the
skin.[22, 69]
Several animal studies have reported a positive association between exposure to PAHs,
oxidative stress, inflammation and development of atherosclerosis[28, 30, 50, 51], a major
underlying risk factor for CVD.[81-83] In addition, occupational studies have reported positive
associations between exposure to PAHs and CVD morbidity and mortality.[33-36] Only one
general population based study has investigated the association between PAH exposure and
CVD, reporting a positive association between PAHs exposure and CVD; however adjustment
for major confounders known to interact with CVD such as diabetes mellitus and cholesterol
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levels and stratification by major characteristics of the study population were not reported in this
paper. [84]
In this context, using a nationally representative sample of United States (US) adults, we
examined the association of eight urinary biomarkers of PAHs; specifically, monohydroxy-PAH
(OH-PAH) and self-reported CVD, independent of serum cotinine, and other potential
confounders. Since exposure to active smoking and SHS are major sources of PAHs, we sought
to determine if this relationship was independent of serum cotinine, self-reported smoking status,
and other potential confounders. Because metabolism and health effects of exposure to PAHs
mixtures were found to be different from that of exposure to individual PAHs [39] , we
additionally created a summed LMW PAH biomarker variable, indicating a graduating level of
exposure to multiple LMW PAHs simultaneously.

METHODS
Study population
The National Health and Nutrition Examination Survey (NHANES) consists of a series of
surveys designed by the National Center for Health Statistics (NCHS) to continuously monitor
the health status of the U.S. civilian non-institutionalized US population. The NHANES survey
includes a stratified multistage probability sample. Selection is based on counties, blocks,
households and individuals within households, and included oversampling of non-Hispanic
Blacks and Mexican Americans in order to provide stable estimates of these groups. After all
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data are collected for a two-year survey cycle, data files are made available for analysis via the
NHANES website.[85, 86]
In the current study we merged 2001-2002, 2003-3004 and 2005-2006 data cycles, where
eight metabolites of PAHs have been consistently measured. Out of 31,509 participants in
NHANES 2001-2006, there are 11, 512 who were 20-65 years of age. Urinary PAHs were only
measured in a subsample of NHANES. We further excluded participants with missing
information on serum cotinine and other covariates that were included in the final model. This
resulted in 2661 participants in final added LMW PAH biomarkers model and 2764 participants
in the final 1-hydroxypyrene model.

Outcome: Self-reported cardiovascular disease
The participant was considered as being a prevalent CVD case if she/he answered “yes”
to any of the following questions: ”Has a doctor or other health professional ever told you that
you have: angina pectoris/ coronary heart disease/ heart attack/ stroke?” (These were 4 separate
questions with the same wording style).

Main exposure: Urinary levels of OH-PAH
Urine specimens were processed, stored, and shipped to the Division of Environmental
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease
Control and Prevention for analysis. Detailed specimen collection and processing instructions are
discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM) [87].
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Vials are stored under appropriate frozen (–20°C) conditions until they are shipped to the
National Center for Environmental Health for testing.
Specific analytes measured in NHANES are monohydroxy-PAH (OH-PAH). The
procedure involves enzymatic hydrolysis of urine, with extraction, derivatization and analysis
using capillary gas chromatography combined with high resolution mass spectrometry (GCHRMS). This method uses isotope dilution with carbon-13 labeled internal standards. Ions from
each analyte and each carbon-13 labeled internal standard are monitored, and the abundance of
each ion is measured. The ratios of these ions are used as criteria for evaluating the data. By
evaluating these analytes in urine, a measurement of the body burden from PAH exposure is
obtained.
Seven urinary LMW PAH analytes, 1-hydroxynapthol, 2- hydroxynapthol, 2hydroxyfluorene, 3-hyrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3hydroxyphenanthrene and one urinary high molecular weight analyte, 1-hydroxypyrene, were
consistently available in NHANES 2001-2006. All analytes were measured in the same unit,
ng/L. Urinary metabolites of PAHs were corrected for creatinine concentration, a urinary marker
of kidney function.[88] Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine
level (mg/dL) multiplied by 0.01, i.e., [(ng/L) ÷ (mg/dL*0.01)] and expressed as nanogram per
gram of creatinine (ng/g creatinine).

Exposure variables
In NHANES, information on age, gender, race/ethnicity, alcohol intake, income, and
cigarette smoking were obtained during a standardized questionnaire during a home interview.
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Information on anthropometric, physical and laboratory components were obtained during the
medical examination center (MEC) examination. Body mass index was calculated as weight in
kilograms divided by height in meters squared. Serum total cholesterol was measured
enzymatically. Seated systolic and diastolic blood pressures were measured using a mercury
sphygmomanometer according to the American Heart Association and JNC7
recommendations.[89] Serum cotinine was measured by an isotope dilution-high performance
liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry (ID
HPLC-APCI MS/MS).[87]
Statistical analysis
Exploratory data analysis techniques were used to assess the presence of any outliers, and
the distribution of all continuous variables was examined. For analysis as continuous variables,
urinary OH-PAH levels were log-transformed as a result of their skewed distribution. We created
a summed low molecular weight PAH biomarker variable by adding the urinary levels of the
metabolites of low molecular weight PAHs (Naphthalene, Fluorene and Phenanthrene).
We ran logistic regression models to calculate the multivariable odds ratio ([OR] and
95% confidence interval [CI]) of self-reported CVD, for each higher urinary OH-PAH quartile
by using the lowest quartile as the referent. Variables were included in the model if they satisfied
two conditions: first, a plausible association with the main outcome that is not causal, and
second, if the percent change of the odds ratio after adjusting for the potential confounder was
over 10 %. Accordingly, final models were adjusted for age (years), sex (men, women), ethnicity
(non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol drinking
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(yes/no), diabetes (absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL),
serum cotinine (ng/mL) and systolic blood pressure (mm Hg).
To further ensure that the association is parallel for subgroups, we performed subgroup
analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that account
for the unequal probabilities of selection, oversampling, and nonresponse in the NHANES
survey were applied for all analyses. Analyses were conducted using SAS (version 9.3, SAS
Institute, Cary, NC) software. Standard errors were estimated using the Taylor series
linearization method.

RESULTS
Table 1 presents baseline characteristics of the study population. About one half of the
study population was female (49.6%). The majority of the study population was non-Hispanic
White (72.2%). The arithmetic mean of serum cotinine was 74.4 ng/mL. Table 2 presents the
sample size, weighted means and percentiles of individual urinary OH-PAH and added
biomarkers of LMW PAHs.
Table 3 presents the results of the analyses measuring the association between urinary
OH-PAH levels and self-reported CVD. Higher quartiles of 1-hydroxynapthalene and additive
biomarkers of LMW PAHs showed positive association with self-reported CVD, when compared
to the lowest quartiles. Using urinary levels of OH-PAH as continuous variables, 1hydroxypyrene showed statistically significant positive association with self-reported CVD.
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Table 4 presents the association between urinary OH-PAH and self-reported CVD by
major sociodemographic characteristics. The positive association between added urinary
biomarkers of LMW PAHs and self-reported CVD was present among subgroups of gender,
race, BMI and smoking. The positive association was stronger among the non-obese subgroup
when compared to the obese group and in current smokers when compared to never and former
smokers. P-interaction values for cross-product terms between added urinary biomarkers of
LMW PAHs and stratifying variables were above >0.10 except for BMI (P=0.002) and smoking
(P=0.002). Urinary levels of 1-hydroxypyrene, the biomarker of the higher molecular weight
PAH pyrene, showed positive association with self-reported CVD within subgroups of gender,
race, BMI and smoking. Some odds ratio failed to reach the conventional levels of statistical
significance. P-interaction values for cross-product terms between urinary levels of 1hydroxypyrene and stratifying variables were above >0.10 except for race (P=0.01).

DISCUSSION
Urinary levels of 1-hydroxynapthalene, 1-hydroxypyrene and added metabolites of LMW
PAH showed positive association with self-reported CVD independent of serum cotinine and
other potential confounders. The positive association was found to be stronger in the non-obese
subgroup when compared to the obese subgroup and among the current smoker subgroup when
compared with the never smoker and the former smoker subgroups. Our results are consistent
with findings from previous occupational studies which reported positive associations between
exposure to PAHs and ischemic heart diseases [33, 34] and cardiovascular mortality in
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occupations that include likely exposure to PAHs such as aluminum smelting, motor vehicle
operators, tar distillation, and asphalt workers.[35, 36]
Polycyclic aromatic hydrocarbons are a group of chemicals formed by the incomplete
combustion organic substances.[16, 21, 45] Exposure to PAHs in the environment is widespread.
Human are usually exposed to mixtures of PAHs.[22] Due to the high cost of detecting parent
PAH levels in humans, the most commonly used biomarkers of PAH exposure are urinary OHPAH metabolites. Urinary OH-PAH biomarkers were used in the current analyses and have been
found to correlate well with levels of exposure to PAHs in the general populations. [24]
Several animal studies have reported positive associations between exposure to PAHs,
oxidative stress and subsequent development of atherosclerosis[28, 30, 50, 51], a major
underlying risk factor for CVD.[81-83] Upon exposure to PAHs, detoxification occurs, leading
to the formation of highly reactive intermediates that can interact with the DNA.[28]
Accordingly, PAH exposure was found to be associated with high levels of PAH-DNA adducts
in arteries in rats.[30] These effects of PAHs exposure on plaque buildup in animals were found
to be dose dependent.[50] Moreover, animal studies have suggested that PAHs might also exert
their atherogenic effect via stimulation of an inflammatory process involving an increased influx
of proinflammatory cells into these plaques.[30] The role of inflammation as a risk factor for
atherosclerosis and CVD development has become well established.[7] Several studies have
shown a positive association between markers of inflammation such as total white blood cell
count and serum C- reactive protein and CVD.[90, 91]
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In the current study, we performed subgroup analysis by gender, race/ethnicity, BMI and
smoking status categories with the intent to examine confounding. In the post-hoc analyses by
BMI, the positive association between urinary OH-PAH and self-reported CVD was found to be
stronger in the non-obese subgroup. PAHs are known to have high affinity for lipid-rich tissues
such as mammary and adipose tissues. [92] The suggested mechanism for the association
between PAH exposure and CVD is through inflammatory PAH-DNA adducts buildup in the
circulatory system. Persons with relatively higher levels of body fat are likely to exhibit
relatively lower PAH activity in the circulation because of the rapid absorption of PAHs by fatty
tissue. [92] Accordingly, higher levels of PAHs in the circulation may be related to higher
inflammatory reaction and eventually the development of cardiovascular diseases. However, it is
possible that the differences we observed are due to random variability and not true causal
differences. Larger studies are needed to confirm if these observed differences in our study are
consistently observed. Similarly in subgroup analysis by smoking status, current smokers
showed stronger association between urinary OH-PAH levels and CVD, when compared to
never and former smokers. This stronger association may be explained by the fact that smoking
is a major risk factor for cardiovascular morbidity and mortality. The population attributable risk
of the smoking of tobacco products on CVD risk has been estimated at 26%.[93]
The main strengths of our study include inclusion of a representative multiethnic sample,
adequate sample size, and the ability to adjust for potential confounders. The high quality of
NHANES data and the rigorous standardized methods used in the data collection add to the
strengths of the study. The main limitation of our study is the cross sectional nature of NHANES
which does not allow to draw temporal or causal inferences regarding the relationship between
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PAHs and self-reported CVD. In addition, our study does not have the data to estimate the
sources of exposure to PAHs. Urinary PAH measurements reflect recent exposure to PAHs if
there are great differences between the current exposure sources and the past exposure sources
for each subject. Finally, CVD was ascertained by self-report. Accordingly, some recollection
bias may exist. However, these biases are likely to be non-differential biases, which would
minimize any observed association.
In summary, in a representative cross-sectional sample of the US population, we found
that higher levels of urinary OH-PAH were positively associated with self-reported CVD.
However, only 1-hydroxynapthalene, 1-hydroxypyrene and added biomarkers of LMW PAHs
were statistically significant. The public health importance of our findings is that there is
evidence, although limited, that background exposure to PAHs is positively associated with CVD
in the US general population. If our findings are replicated in future larger prospective studies,
the population-attributable risk of PAH exposure on CVD risk could potentially be high.
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Table 1. Baseline characteristics of the study population 20-65 years of age with measured
urinary levels of OH-PAH (n=2661)
Mean values ± (Std error of mean) or
Characteristics
Sample size (weighted percentages)
Female (%)
1354 (49.6)
Age (years)
41.0 ± (0.32)
Race/Ethnicity (%)
Non-Hispanic Whites
1332 (72.2)
Non-Hispanic Blacks
551 (10.6)
Others
778 (17.3)
Education categories (%)
Less than high school
637 (14.4)
High school
619 (24.7)
Above high school
1405 (60.9)
Below poverty level (%)
461 (12.6)
Smoking categories (%)
Never
1395 (50.5)
Former smokers
559 (21.5)
Current smokers
707 (26.0)
Alcohol drinking (%)
No
742 (23.7)
Yes
1919 (76.3)
Body mass index (%)
Normal weight (<25.0 kg/m2)
824 (34.3)
Overweight (25.0-29.9 kg/m2)
901 (31.8)
2
Obese (>30.0 kg/m )
936 (33.9)
Serum cotinine (ng/mL)
74.4 ± (3.84)
Total cholesterol (mg/dL)
201.3 ± (1.33)
Systolic blood pressure (mmHg)
119.3± (0.47)
CVD (%)
138(4.9)
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis
Chemicals
Selected percentiles
th
th
Sample
Mean
Minimum
10
25
50th
75th
size

90th

Maximum

1- Hydroxynaphthalene
2-Hydroxynaphthalene

2785
2794

41708
6263.3

50.8
9.2

488.7
798.4

832.6
1356.5

1996.3
2885.2

7120.0
7952.5

17952
16001

39226536
404573

2-Hydroxyfluorene
3-Hydroxyfluorene

2767
2751

651.3
334.5

2.2
1.2

102.8
34.4

144.0
52.3

245.6
96.7

752.1
400.7

1740.4
1004.8

29914
19084

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2773
2747
2745

214.1
96.6
188.5

0.7
0.5
0.7

60.8
22.7
37.6

89.4
35.7
55.0

140.9
58.4
90.7

234.6
101.7
173.8

370.2
178.4
333.7

8341.9
5069.4
20248

1-Hydroxypyrene

2764

134.4

0.9

22.5

35.8

65.9

136.6

270.4

10014

Summed LMW PAH biomarkers

2661

50970

508.8

2131.3

3180.1

6207.5

18772

38592

39235478

60

Table 3: Logistic regression: Association of urinary levels of OH-PAH (ng/g creatinine) and self-reported cardiovascular disease
Chemicals
Sample size
Quartile 1
Quartile 2
Quartile 3
Quartile 4
Log-PAH
Odds ratio (95% confidence interval)*
2785
1 (Referent)
1.62(0.85, 3.12)
1.44(0.62, 3.35)
2.78(1.35, 5.72)
1.14(0.99, 1.32)
1-Hydroxynaphthalene
2794
1 (Referent)
1.32(0.70, 2.48)
1.31(0.64, 2.67)
2.12(0.98, 4.58)
1.26(0.98, 1.63)
2-Hydroxynaphthalene
2-Hydroxyfluorene
3-Hydroxyfluorene

2767
2751

1 (Referent)
1 (Referent)

1.22(0.62, 2.44)
0.70(0.42, 1.18)

1.17(0.60, 2.28)
0.74(0.40, 1.38)

2.04(0.99, 4.25)
1.46(0.78, 2.76)

1.22(0.99, 1.50)
1.14(0.94, 1.38)

1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene

2773
2747
2745

1 (Referent)
1 (Referent)
1 (Referent)

0.46(0.25, 0.86)
0.91(0.49, 1.66)
0.68(0.31, 1.47)

0.73(0.41, 1.30)
1.25(0.64, 2.42)
1.27(0.63, 2.55)

1.25(0.71, 2.18)
1.42(0.78, 2.60)
1.38(0.74, 2.58)

1.07(0.86, 1.34)
1.04(0.86, 1.28)
1.10(0.86, 1.41)

1-Hydroxypyrene

2764

1 (Referent)

1.06(0.53, 2.15)

1.21(0.57, 2.57)

1.87(0.89, 3.94)

1.26(1.04, 1.53)

Summed LMW PAH
2661
1 (Referent)
1.24(0.66, 2.34)
1.23(0.57, 2.65)
2.27(1.03, 5.02)
1.17(0.96, 1.42)
biomarkers
*Adjusted for age (years), sex (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol (yes, no), BMI (normal
weight, overweight, obese), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic blood
pressure (mmHg).
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Table 4: Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and self-reported cardiovascular diseases by sociodemographic
characteristics
Subgroups
Summed urinary levels LMW PAH biomarkers
1-hydroxypyrene
Multivariable odds ratio of CVD
Gender*
Male
Females

1.24(0.88, 1.75)
1.11(0.92, 1.34)

Race-ethnicity*
Non-Hispanic whites
All others

1.18(0.94, 1.49)
1.14(0.81, 1.60)

Body mass index+
Non obese
Obese

p-interaction
0.64

Multivariable odds ratio of CVD
1.28(1.01, 1.64)
1.25(0.89, 1.73)

0.41

0.01
1.35(1.08, 1.69)
1.03(0.76, 1.41)

0.002
1.43(1.13, 1.82)
1.05(0.83, 1.33)

p-interaction
0.27

0.26
1.39(1.05, 1.82)
1.15(0.90, 1.47)

0.002
0.15
Smoking*
1.21(0.93, 1.56)
1.06(0.72, 1.57)
Never smokers
0.77(0.43,
1.38)
1.14(0.80, 1.63)
Former smokers
2.59(1.29, 5.19)
1.79(1.06, 3.02)
Current smokers
* Adjusted for age (years), gender (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol intake (yes, no), BMI
(normal weight, overweight, obese), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic
blood pressure (mmHg) except stratified variables
+ Adjusted for age (years), gender (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol intake (yes, no), BMI
(Kg/m2), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic blood pressure (mmHg).
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Conclusion
Cardiovascular disease is the number one cause death and diabetes mellitus is the seventh
leading cause of death in the US adults. [72] The burden of cardiovascular disease and diabetes
mellitus is continuing to grow. It has been shown that the traditional risk factors for CVD and
diabetes may not explain all of the observed risk of these diseases. Environmental pollutants
have been recently proposed as a novel CVD and diabetes mellitus risk factor in the general
population. In the current study, urinary biomarkers of the low molecular weight polycyclic
aromatic hydrocarbons (Naphthalene, Fluorene and Phenanthrene) and to lesser extent the higher
molecular weight Pyrene were significantly associated with high serum C-reactive protein, high
total white blood cell count, and diabetes mellitus independent of serum cotinine, self-reported
smoking status and other potential confounders. The previous evidence on the association of
urinary biomarker of polycyclic aromatic hydrocarbons and self-reported cardiovascular disease
is limited.
These new results, consistent with previous animal and occupational studies[27], suggest that
the low background exposure to polycyclic aromatic hydrocarbons may be related to low grade
inflammation, evident by baseline elevations in serum CRP and total WBC count. The study also
provides evidence on the associations between low background exposure to polycyclic aromatic
hydrocarbons and diabetes mellitus and CVD. The mechanism underlying these associations may
be through chronic low grade inflammation. Low grade inflammation has been implicated in the
development of atherosclerosis and subsequent development of CVD.[7] Inflammation has been
also suggested as a risk factor for insulin resistance[6] and subsequent development of diabetes
mellitus.[8]
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Despite the consistency and biological plausibility, the clinical significance of our findings is
still unknown. Prospective studies are necessary to confirm or refute our findings. Because
exposure to polycyclic aromatic is widespread in the environment, and due to the high
prevalence of diabetes and CVD, the population attributable risk due to polycyclic aromatic
hydrocarbons exposure could be high. Polycyclic aromatic hydrocarbons occur from both natural
as well as anthropogenic sources. Efforts to decrease the concentration of PAHs in the ambient
air can be rewarding. Similar policies, such as anti-smoking bans were associated with a
significant decrease in the incidence of cardiovascular disease.95, 96
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